{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:34:02Z","timestamp":1781123642144,"version":"3.54.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007368","name":"Fondazione Pisa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA21116"],"award-info":[{"award-number":["CA21116"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105299","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:40:32Z","timestamp":1774543232000},"page":"105299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Eph receptors in pancreatic cancer: Biological roles and clinical implications"],"prefix":"10.1016","volume":"222","author":[{"given":"Karlijn A.","family":"van de Langerijt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Westveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Kazemier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godefridus J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa Y.S.","family":"le Large","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7565-7504","authenticated-orcid":false,"given":"Elisa","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.critrevonc.2026.105299_bib1","doi-asserted-by":"crossref","first-page":"10651","DOI":"10.3390\/cimb46090632","article-title":"The role of biomarkers in the early diagnosis of gastric cancer: a study on CCR5, CCL5, PDGF, and EphA7","volume":"46","author":"Bademler","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105299_bib2","doi-asserted-by":"crossref","first-page":"15443","DOI":"10.1021\/acs.jmedchem.2c01391","article-title":"Targefrin: a potent agent targeting the ligand binding domain of EphA2","volume":"65","author":"Baggio","year":"2022","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105299_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157694","article-title":"Notch-mediated Ephrin signaling disrupts islet architecture and \u03b2 cell function","volume":"7","author":"Bartolom\u00e9","year":"2022","journal-title":"JCI Insight"},{"issue":"46","key":"10.1016\/j.critrevonc.2026.105299_bib4","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1038\/sj.onc.1205679","article-title":"Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo","volume":"21","author":"Brantley","year":"2002","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105299_bib5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/13543784.2020.1762566","article-title":"The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment","volume":"29","author":"Buckens","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105299_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2023.149214","article-title":"An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment","volume":"688","author":"Chang","year":"2023","journal-title":"Biochem Biophys. Res Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105299_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21774","article-title":"Effectiveness of anti-erythropoietin producing Hepatocellular receptor Type-A2 antibody in pancreatic cancer treatment","volume":"9","author":"Chang","year":"2023","journal-title":"Heliyon"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105299_bib8","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/sj.bjc.6604676","article-title":"Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer","volume":"99","author":"Chang","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105299_bib9","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190610","article-title":"Qingyihuaji formula reverses gemcitabine resistant human pancreatic cancer through regulate lncRNA AB209630\/miR-373\/EphB2-NANOG signals","volume":"39","author":"Chen","year":"2019","journal-title":"Biosci. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105299_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1476-5586(03)80047-7","article-title":"Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors","volume":"5","author":"Cheng","year":"2003","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105299_bib11","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.2147\/DDDT.S60328","article-title":"Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies","author":"Chiorean","year":"2015","journal-title":"Drug Des. Devel Ther. 9"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105299_bib12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/0008-5472.CAN-3430-2","article-title":"Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist","volume":"64","author":"Dobrzanski","year":"2004","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105299_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/jphp.12941","article-title":"Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer","volume":"71","author":"Du","year":"2019","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105299_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.844527","article-title":"Molecular landscape and prognostic biomarker analysis of advanced pancreatic cancer and predictors of treatment efficacy of AG Chemotherapy","volume":"12","author":"Du","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105299_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/biom14060692","article-title":"Advances in integrated multi-omics analysis for drug-target identification","volume":"14","author":"Du","year":"2024","journal-title":"Biomolecules"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105299_bib16","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.7150\/thno.26650","article-title":"Chemoresistance transmission via exosome-mediated EphA2 transfer in pancreatic cancer","volume":"8","author":"Fan","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105299_bib17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.canlet.2015.12.020","article-title":"Current progress in immunotherapy for pancreatic cancer","volume":"381","author":"Foley","year":"2016","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105299_bib18","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.21873\/anticanres.14938","article-title":"Ephrin receptor A4 expression enhances migration, invasion and neurotropism in pancreatic ductal adenocarcinoma cells","volume":"41","author":"Furuhashi","year":"2021","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105299_bib19","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1021\/acschembio.8b00556","article-title":"Structure-based design of novel EphA2 agonistic agents with nanomolar affinity in vitro and in cell","volume":"13","author":"Gambini","year":"2018","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105299_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12253-009-9221-6","article-title":"Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma","volume":"16","author":"Giaginis","year":"2010","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.critrevonc.2026.105299_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14646","article-title":"Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent EphA2 trafficking to promote cell:cell repulsion","volume":"8","author":"Gundry","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105299_bib22","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3892\/ijo.2014.2500","article-title":"Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE\u2011cadherin\/EphA2\/MMP9\/MMP2 expression","volume":"45","author":"Guo","year":"2014","journal-title":"Int J. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105299_bib23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105299_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105299_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.biopha.2010.12.011","article-title":"Promoted cancer growth by stimulating cell proliferation and decreasing apoptosis using a lentivirus-based EphB2 RNAi in pancreatic carcinoma CFPAC-1 cells","volume":"65","author":"Hua","year":"2011","journal-title":"Biomed. Pharm."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105299_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cell.2007.02.044","article-title":"EphA-Ephrin-A-mediated beta cell communication regulates insulin secretion from pancreatic islets","volume":"129","author":"Konstantinova","year":"2007","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105299_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.545","article-title":"Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer","volume":"8","author":"Koshikawa","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105299_bib28","article-title":"Advances and current concepts on Eph receptors and ephrins in upper digestive tract cancers","volume":"14","author":"Lavareze","year":"2024","journal-title":"Front. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105299_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138290","article-title":"Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets","volume":"5","author":"Le Large","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.critrevonc.2026.105299_bib30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.semcancer.2024.09.002","article-title":"Unravelling the complexities of resistance mechanism in pancreatic cancer: insights from in vitro and ex-vivo model systems","volume":"106-107","author":"Lencioni","year":"2024","journal-title":"Semin Cancer Biol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105299_bib31","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-18-2811","article-title":"Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination","volume":"25","author":"Lennon","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105299_bib32","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1007\/s13277-014-1937-6","article-title":"EphB4 regulates the growth and migration of pancreatic cancer cells","volume":"35","author":"Li","year":"2014","journal-title":"Tumour Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105299_bib33","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s11033-012-2224-5","article-title":"Clinical implications of EphB4 receptor expression in pancreatic cancer","volume":"40","author":"Li","year":"2013","journal-title":"Mol. Biol. Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105299_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167346","article-title":"BCL6 overexpression in CD4(+) T cells induces Tfh-like transdifferentiation and enhances antitumor efficiency of CAR-T therapy in pancreatic cancer","volume":"1870","author":"Lin","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105299_bib35","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.3892\/ol.2014.2011","article-title":"Involvement of ephrin receptor A4 in pancreatic cancer cell motility and invasion","volume":"7","author":"Liu","year":"2014","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105299_bib36","article-title":"Prognostic and therapeutic value of the Eph\/Ephrin signaling pathway in pancreatic cancer explored based on bioinformatics","volume":"14","author":"Liu","year":"2024","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105299_bib37","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3892\/ol.2012.650","article-title":"Overexpression of the B-type Eph and ephrin genes correlates with progression and pain in human pancreatic cancer","volume":"3","author":"Lu","year":"2012","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105299_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamasurg.2023.7872","article-title":"Implementation of best practices in pancreatic cancer care in the netherlands: a stepped-wedge randomized clinical trial","volume":"159","author":"Mackay","year":"2024","journal-title":"JAMA Surg."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105299_bib39","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1172\/JCI127755","article-title":"Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2)","volume":"129","author":"Markosyan","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105299_bib40","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.22.02770","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group","volume":"41","author":"Moore","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105299_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.852236","article-title":"Roles of Eph-Ephrin signaling in the eye lens cataractogenesis, biomechanics, and homeostasis","volume":"10","author":"Murugan","year":"2022","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105299_bib42","series-title":"A Pilot Multi-arm Study of sEphB4-HSA in Combination With Different Chemotherapy Regimens in Patients With Specific Advanced or Metastatic Solid Tumors, in: National Cancer, I.","author":"NCT02495896","year":"2015"},{"key":"10.1016\/j.critrevonc.2026.105299_bib43","series-title":"A Phase-1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors","author":"NCT03076372","year":"2017"},{"key":"10.1016\/j.critrevonc.2026.105299_bib44","series-title":"A study of BT5528 in Patietns with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","author":"NCT07450859","year":"2026"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105299_bib45","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/dvdy.22584","article-title":"Pancreas organogenesis: from bud to plexus to gland","volume":"240","author":"Pan","year":"2011","journal-title":"Dev. Dyn."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105299_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-023-00634-x","article-title":"Eph receptors and ephrins in cancer progression","volume":"24","author":"Pasquale","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105299_bib47","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ccell.2024.08.001","article-title":"The KRAS mutational spectrum and its clinical implications in pancreatic cancer","volume":"42","author":"Perelli","year":"2024","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105299_bib48","doi-asserted-by":"crossref","first-page":"22245","DOI":"10.1021\/acs.jmedchem.4c02286","article-title":"Constrained \u03b2-hairpins targeting the EphA4 ligand binding domain","volume":"67","author":"Prentiss","year":"2024","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105299_bib49","doi-asserted-by":"crossref","first-page":"17103","DOI":"10.18632\/oncotarget.7931","article-title":"Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine","volume":"7","author":"Quinn","year":"2016","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105299_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143404","article-title":"Tyrosine phosphoproteomics of patient-derived xenografts reveals ephrin type-B receptor 4 tyrosine kinase as a therapeutic target in pancreatic cancer","volume":"13","author":"Renuse","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105299_bib51","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1021\/acs.nanolett.9b02232","article-title":"Rapid lipid-based approach for normalization of quantum-dot-detected biomarker expression on extracellular vesicles in complex biological samples","volume":"19","author":"Rodrigues","year":"2019","journal-title":"Nano Lett."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105299_bib52","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/jpp\/rgad055","article-title":"Homoharringtonine sensitizes pancreatic cancer to erlotinib by direct targeting and miRNA-130b-3p-mediated EphB4-JAK2-STAT3 axis","volume":"75","author":"Sarwar","year":"2023","journal-title":"J. Pharm. Pharm."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105299_bib53","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1158\/2767-9764.CRC-23-0087","article-title":"EphA2 proteolytic fragment as a sensitive diagnostic biomarker for very early-stage pancreatic ductal carcinoma","volume":"3","author":"Sato","year":"2023","journal-title":"Cancer Res Commun."},{"key":"10.1016\/j.critrevonc.2026.105299_bib54","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-94-017-7215-0_15","article-title":"CA 19-9: biochemical and clinical aspects","volume":"867","author":"Scar\u00e0","year":"2015","journal-title":"Adv. Exp. Med Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105299_bib55","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/13813455.2020.1762658","article-title":"Circulating microRNA-944 and its target gene EPHA7 as a potential biomarker for colorectal cancer","volume":"128","author":"Shaker","year":"2022","journal-title":"Arch. Physiol. Biochem."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105299_bib56","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.7150\/thno.106948","article-title":"EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment","volume":"15","author":"Sharma","year":"2025","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105299_bib57","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1111\/cas.14568","article-title":"The catalytically defective receptor protein tyrosine kinase EphA10 promotes tumorigenesis in pancreatic cancer cells","volume":"111","author":"Shin","year":"2020","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105299_bib58","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41416-025-03025-1","article-title":"Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study","volume":"133","author":"Stoop","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"38","key":"10.1016\/j.critrevonc.2026.105299_bib59","doi-asserted-by":"crossref","first-page":"41063","DOI":"10.18632\/oncotarget.5729","article-title":"Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice","volume":"6","author":"Takano","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105299_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26123687","article-title":"Effective tumor targeting by EphA2-agonist-biotin-streptavidin conjugates","volume":"26","author":"Udompholkul","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105299_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1756-9966-31-68","article-title":"Molecular markers associated with outcome and metastasis in human pancreatic cancer","volume":"31","author":"Van den Broeck","year":"2012","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105299_bib62","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.modgep.2005.09.010","article-title":"Eph receptors and their ephrin ligands are expressed in developing mouse pancreas","volume":"6","author":"van Eyll","year":"2006","journal-title":"Gene Expr. Patterns"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105299_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050588","article-title":"Clinical trials targeting the stroma in pancreatic cancer: a systematic review and meta-analysis","volume":"11","author":"van Mackelenbergh","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105299_bib64","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/MPA.0000000000001660","article-title":"Serum Exo-EphA2 as a potential diagnostic biomarker for pancreatic cancer","volume":"49","author":"Wei","year":"2020","journal-title":"Pancreas"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105299_bib65","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.chembiol.2015.06.011","article-title":"Design and characterization of novel EphA2 agonists for targeted delivery of chemotherapy to cancer cells","volume":"22","author":"Wu","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.critrevonc.2026.105299_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109972","article-title":"EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53\/p21 pathway and EMT","volume":"125","author":"Zhu","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105299_bib67","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231218559","article-title":"Identification of therapeutic targets and prognostic biomarkers of the ephrin receptor subfamily in pancreatic adenocarcinoma","volume":"52","author":"Zou","year":"2024","journal-title":"J. Int. Med. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:45:21Z","timestamp":1778481921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":67,"alternative-id":["S1040842826001861"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105299","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eph receptors in pancreatic cancer: Biological roles and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105299"}}